Orforglipron and Pancreatitis: What the FDA Label Says About the Risk

Yes — the FDA-approved FOUNDAYO (orforglipron) label lists acute pancreatitis as a warning, with cases reported in patients on the drug. It’s not unique to orforglipron; pancreatitis is flagged as a consideration across GLP-1 receptor agonists as a class. Here’s what the label actually says, the symptoms that matter, and how it’s different from the everyday GI side effects orforglipron is better known for.

What the FOUNDAYO Label Says About Pancreatitis

Per the FDA-approved label on DailyMed, orforglipron may cause serious side effects, including inflammation of the pancreas. Acute pancreatitis has been reported in patients treated with orforglipron, and the label notes that fatal and non-fatal hemorrhagic or necrotizing pancreatitis have been observed in patients treated with GLP-1 receptor agonists as a class. The label instructs patients to be informed of the potential risk and its symptoms, and to discontinue orforglipron promptly and contact their healthcare provider if pancreatitis is suspected.

Notably, the label doesn’t publish a specific incidence rate — a percentage of patients affected — for pancreatitis with orforglipron, so this article isn’t going to invent one. What it does make clear is that this is a recognized, labeled risk, not a rare footnote to dismiss.

What Are the Symptoms to Watch For?

The symptom pattern the label describes is specific, and worth distinguishing from ordinary GLP-1 side effects:

• Severe abdominal pain — often described as intense, not the mild cramping some people get with dose increases
• Pain that may radiate to the back
• May or may not include nausea or vomiting — so pain alone, without other GI symptoms, still counts

This is different from the common, usually milder GI side effects associated with orforglipron — nausea, vomiting, diarrhea, and constipation — which our orforglipron side effects guide covers in more detail. Ordinary nausea is expected and often improves over time; severe, persistent, radiating abdominal pain is not something to wait out.

Is This an Orforglipron-Specific Risk, or a GLP-1 Class Effect?

Based on drug labeling and information for the major GLP-1-class medications, pancreatitis appears as a warning across the class, not something singled out for orforglipron:

	Orforglipron (Foundayo)	Semaglutide (Ozempic/Wegovy)	Tirzepatide (Mounjaro/Zepbound)
Mechanism	GLP-1 receptor agonist (small molecule)	GLP-1 receptor agonist (peptide)	Dual GIP/GLP-1 receptor agonist (peptide)
Pancreatitis noted in drug information	Yes — FDA label warning	Yes — flagged in drug information	Yes — flagged in drug information
Symptom pattern described	Severe abdominal pain, may radiate to back	Similar GI/abdominal warning pattern	Similar GI/abdominal warning pattern

Sources: FOUNDAYO FDA label (DailyMed) and the MedlinePlus semaglutide and tirzepatide pages, linked below. This table reflects that all three share the warning in their respective drug information — it does not claim one drug’s risk is higher or lower than another’s, because no head-to-head incidence comparison is being cited here.

Gallbladder Problems: A Related but Separate Warning

The FOUNDAYO label also separately warns about acute gallbladder disease, reported in clinical trials. If cholecystitis (gallbladder inflammation) is suspected, the label notes that gallbladder studies and clinical follow-up are indicated. Symptoms to report to your prescriber right away include:

• Pain in the upper abdomen
• Fever
• Yellowing of the skin or eyes (jaundice)
• Clay-colored stools

This is a distinct warning from pancreatitis, though both involve the upper abdomen and both call for prompt medical attention rather than waiting to see if symptoms pass.

Who Might Be at Higher Risk?

The FOUNDAYO label doesn’t break down specific risk factors that raise or lower an individual’s chance of pancreatitis on orforglipron, and this article won’t speculate on numbers the label doesn’t provide. What it does establish is the baseline: this is a known risk category for the drug, which is exactly why your prescriber will typically ask about your history — including any prior pancreatitis, gallstones, or other relevant conditions — before and during treatment. If you have a personal or family history of pancreatitis or gallbladder disease, that’s worth raising with your prescriber directly rather than assuming it does or doesn’t change your risk. (For a different labeled warning — the thyroid C-cell tumor boxed warning — see does orforglipron cause thyroid cancer?)

What To Do If You Suspect Pancreatitis

If you’re on orforglipron and experience severe abdominal pain — especially pain radiating to your back, with or without nausea or vomiting — the FDA label’s guidance is clear: stop taking the medication and contact your healthcare provider promptly. Severe or worsening abdominal pain is also a reasonable reason to seek emergency care rather than waiting for a scheduled appointment, since pancreatitis can escalate quickly.

This is different from the routine nausea or GI adjustment many people experience when starting or titrating orforglipron, which our Foundayo dosing guide and managing orforglipron nausea article walk through. The distinction matters: don’t ignore severe pain by assuming it’s “just” the usual GI side effects, and don’t panic over ordinary nausea assuming it’s pancreatitis. If you’re ever unsure which one you’re dealing with, that uncertainty itself is a reason to call your prescriber rather than guess.

Bottom Line

Pancreatitis is a real, FDA-labeled warning for orforglipron (Foundayo) — not a rumor and not unique to this drug, since it shows up across GLP-1-class medications in their respective drug information. The label doesn’t quantify exactly how common it is, so this article won’t either. What matters practically is recognizing the specific symptom pattern — severe abdominal pain, possibly radiating to the back — and knowing that the labeled guidance is to stop the medication and contact your prescriber promptly if you suspect it. This is educational information based on the FDA label and standard drug references, not medical advice; your prescriber is the right person to assess your individual risk and any symptoms you’re experiencing.